The highest focus of NexACT enhancer tested did not affect the viability of the buccal cells, suggesting a safe range for clinical make use of. Dr. Bassam Damaj, President and CEO of Apricus Bio, noted, ‘The buccal path of delivery represents an additional, new program of NexACT and potentially enables us to provide drugs that can’t be shipped via the oral, intravenous or transdermal route.’ The abstract is available at:.. Apricus announces publication of NexACT technology data in Pharmaceutics Journal Apricus Biosciences, Inc. This article, entitled, ‘Enhanced in vitro Transbuccal Medication Delivery of Ondansetron HCl,’ highlights NexACT enhancers’ ability to considerably improve permeation of ondansetron, a medication used to take care of vomiting and nausea connected with chemotherapy and post surgery, through porcine buccal tissue.HCl, among the NexACT technology’s proprietary enhancers, provided the best improvements when compared to various other enhancers and other technology .Jeff Bingaman, Sen. Tom Udall, Rep. Martin Heinrich, Rep. Ben Ray Lujan, and Rep. The stigma of smoking cigarettes continues to undermine study funding efforts despite the fact that over 60 percent of fresh instances are diagnosed in individuals who hardly ever smoked or who experienced already quit, most of them years ago. Just 16 percent will end up being diagnosed at an early on treatable stage, & most will die within a couple of months. Related StoriesNew antenna-like gadget makes breast cancer medical procedures less difficult for surgeonsMD Anderson research reveals why chemotherapy medications not effective for most pancreatic cancer patientsNew results reveal association between colorectal cancer tumor and melanoma prescription drugs.